Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
103 results about "TLR3" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Toll-like receptor 3 (TLR3) also known as CD283 (cluster of differentiation 283) is a protein that in humans is encoded by the TLR3 gene. TLR3 is a member of the toll-like receptor family of pattern recognition receptors of the innate immune system.
Small molecule toll-like receptor (TLR) antagonists
The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.
Owner:COLEY PHARMA GMBH +1
Small molecule toll-like receptor (TLR) antagonists
The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.
Owner:COLEY PHARMA GMBH +1
RNAi-based therapeutics for allergic rhinitis and asthma
InactiveUS20060058255A1Suppress gene expressionGood curative effectAntibacterial agentsSpecial deliveryTLR8Disease
The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and / or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent / delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.
Owner:MASSACHUSETTS INST OF TECH
Treatment of cancer using TLR3 agonists
ActiveUS20060110746A1Conducive to survivalGood curative effectActivity regulationMicrobiological testing/measurementCancer cellAgonist
Owner:INSTITUT GUSTAVE ROUSSY
Method for enhancing immunological performance and migration capacity of adipose mesenchymal stem cell
InactiveCN104845933AStrong immunosuppressive abilityIncreased secretion of TGF-βSkeletal/connective tissue cellsMesenchymal stem cellSecretory cell
The invention relates to the technical field of adipose mesenchymal stem cells in the technical field of cell therapy, in particular to a method for enhancing an immune regulating function and a migration capacity of adipose mesenchymal stem cells. Primary culture and secondary culture are performed to the adipose mesenchymal stem cells obtained through separation, and then short-time culture is performed by using culture medium containing low-concentration TLR3 activator Poly(I:C). After Poly(I:C) co-stimulation culture is performed, the obtained adipose mesenchymal stem cells with a brand new phenotype have a stronger migration capacity, the levels of secreting cytokine and chemotactic factor are changed and a stronger immunosuppressive function is reflected on the whole.
Owner:DALIAN UNIV OF TECH
Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
InactiveUS20100004304A1Mitigating and preventing complicationOrganic active ingredientsBiocideLymphatic SpreadGrowth cell
It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3 exists in vitro in pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells with high basal expression of Toll-like receptor 3 (TLR3) and Wnt5a. IL6 / STAT3 activation, mediated by overexpressed TLR3 signaling, appears important in the tumor growth process, it may increase Wnt5a signaling, and be associated with increased cellular growth and migration. Using a novel inhibitor of pathologic TLR3 signaling (5-phenylmethimazole [C10]) we have demonstrated decreases in these markers plus suppression of cell growth and migration in human pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells.
Owner:OHIO UNIV
Toll like receptor 3 antagonists, methods and uses
Owner:CARTON JILL M +17
Use of tlr3 agonists for the treatment of neurodegenerative disorders
InactiveUS20090253622A1Increase productionHigh activityNervous disorderPeptide/protein ingredientsAgonistHistiocyte
The present invention relates to a method for the treatment and / or prophylaxis of a degenerative inflammatory process in a tissue of a subject, said method comprising increasing the activity of Toll-like receptor 3 (TLR3) in cells of said tissue. In a preferred embodiment, the TLR3 agonist is stathmin or stathmin-like proteins such as SCGIO, SCLIP or RB3.
Owner:NEDERLANDSE ORG VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK (TNO)
Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
ActiveUS20170226221A1Reducing growth kineticsOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsMonoclonal antibodyTumor antigen
The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.
Owner:CANARIABIO INC
Tlr3 binding agents
ActiveUS20120034232A1Efficient high affinity bindingStrong inhibitory activityAntibacterial agentsBacteriaAntibody fragmentsAutoimmune disease
The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.
Owner:INNATE PHARMA SA
Methods and compositions combining immunotherapy with monocyte activation
Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells to a subject in need of such treatment. The subject may have cancer, an autoimmune disease, an infectious disease or an immunodeficiency. The composition capable of preferentially activating monocytes or macrophages may be a TLR3 agonist. The composition capable of preferentially depleting B10 cells may be a CD19 antibody. Pharmaceutical compositions comprising an antibody-based therapeutic agent and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells are also provided.
Owner:DUKE UNIV
Treatment of cancer using TLR3 agonists
ActiveUS7378249B2Good curative effectImprove survivalActivity regulationMicrobiological testing/measurementCancer cellAgonist
Owner:INSTITUT GUSTAVE ROUSSY
Detection system for detecting human immune state
The invention relates to a detection system for detecting a human immune state and belongs to the technical field of gene detection. The detection system provided by the invention is used for detecting 20 genes, including IFI27, ISG15, IFI44L, RSAD2, HERC5, IFITM3, IFI44, IFIT3, EPSTI1, IFIT1, HP, ANXA3, ARG1, FCGR1B, S100A12, MMP9, IL18R1, TLR3, GYG1 AND FCGR1A in peripheral blood; the assessment for the human immune state can be realized in the manner of increasing or reducing the expression level of each gene; and the genes are utilized to guide accurate medical treatment, including disease accurate parting, prognosis, treatment tracking and therapeutic evaluation. The detection system has excellent clinic application values and wide application prospects.
Owner:BEIJING INST OF GENOMICS CHINESE ACAD OF SCI CHINA NAT CENT FOR BIOINFORMATION
Compositions and Methods for Detecting TLR3
The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.
Owner:INNATE PHARMA SA
Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
Owner:GENMAB AS
Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
ActiveUS20120009206A1Trend downStrong specificityAntibacterial agentsOrganic active ingredientsImmunologic disordersChemical structure
A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C30,U) has a reduced tendency to form branched dsRNA which results in increased bioactivity due to an increased ability to bind TLR3 receptor. Pharmaceutical formulations containing the new nucleic acid as active ingredients and methods of treatment are also provided. The invention also provides a description of the physicochemical properties of this novel form of Rugged dsRNA and a method for its preparation in substantially pure form. DsRNAs acting thru TLR3 receptor activation are potent antiviral compounds as well as anticancer agents; also through secondary immunomodulation they can enhance the bioactivity of vaccines and also treat autoimmune disorders.
Owner:AIM IMMUNOTECH INC
TLR3 Glycosylation Site Muteins and Methods of Use
InactiveUS20070203064A1Decreasing TLR glycosylationModulate activityBiocidePeptide/protein ingredientsMutant proteinGlycosylation
TLR3 glycosylation site muteins, nucleic acids encoding the muteins, and methods of modulating TLR3 activity in a cell are disclosed.
Owner:CENTOCOR
TLR3 binding agents
ActiveUS9388246B2Inhibit TLR signalingAvoid signalingAntibacterial agentsAntipyreticAutoimmune conditionAntibody fragments
Owner:INNATE PHARMA SA
Compound adjuvant for tuberculosis subunit vaccine, tuberculosis subunit vaccine from same and preparation method and application thereof
InactiveCN103203018AImproving immunogenicityHelps induce Th1 type anti-TB immune responseAntibacterial agentsBacterial antigen ingredientsAdjuvantNucleotide
The present invention discloses a compound adjuvant for tuberculosis subunit vaccine, containing cationic liposome dimo-thylidioctyl ammonium bromide (DDA), TLR9 ligand CpG oligodeoxynucleotides 2395 and TLR3 ligand PolyICLC, and also provides the tuberculosis subunit vaccine and preparation method and application thereof. The beneficial effect of the invention is that the compound adjuvant for tuberculosis subunit vaccine provided by the present invention enhances the immunogenicity of the fusion protein of Mycobacterium tuberculosis, contributing to the induction of the tuberculosis fusion protein to Th1-type anti-tuberculosis immune response.
Owner:LANZHOU UNIVERSITY
Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
InactiveUS20120064095A1Inhibit inflammationEffective amountPeptide/protein ingredientsMetabolism disorderPolynucleotideAntagonist
Owner:JANSSEN BIOTECH INC
TLR3 Agonist Compositions
InactiveUS20110076296A1Improve performanceHigh activityOrganic active ingredientsGenetic material ingredientsDiseaseMedicine
The present invention relates generally to the fields of medicine. More specifically, the present invention relates to improved TLR3 agonists. The present invention provides novel dsRNA such as polyAU composition useful in the treatment of TLR3 related diseases, uses and preparations thereof.
Owner:INNATE PHARMA SA
Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide binding protein beta 2-like 1 (GNB2L1), guanine nucleotide binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low density lipoprotein receptor-related protein 4 (LRP4), human glomerular epithelial protein 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and / or biological activity of said proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and / or biological activity of said proteins including using agents identified in screening assays described herein, vector delivery of antisense polynucleotide sequences, and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin.
Owner:GENMAB AS
Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
Owner:JANSSEN BIOTECH INC
TOLL like receptor 3 antagonists, methods and uses
ActiveCN101415438AIncrease proliferation rateExtension of timeImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsPolynucleotideBiology
Owner:CENTOCOR
Fluorescent quantitative PCR detection method for TLR3 (toll-like receptors) gene of duck
InactiveCN104651503AImprove reliabilityGood repeatabilityMicrobiological testing/measurementVector-based foreign material introductionSolubilityPlasmid copy number
The invention provides a fluorescent quantitative PCR detection method for a TLR3 (toll-like receptors) gene of a duck. The detection method comprises the following steps: by taking a recombinant plasmid Peasy-T5-TLR3 as a template, screening the optimum concentration of a primer, a fluorescent quantitative PCR reaction system and a reaction condition; by taking the recombinant plasmid as a standard substance, determining the OD260 value; according to the molecular weight and the mass concentration, calculating the copy concentration, diluting, carrying out FQ-PCR amplification; by taking logarithm of the recombinant plasmid copy number as axis X and circulating number of times as axis Y, establishing a standard curve; repeatedly verifying 1.0*10<3>-1*10<8> copy / microliter recombinant plasmid; carrying out FQ-PCR detection on the recombinant plasmid; and carrying out double verification on the specificity of the detection method by virtue of sequence alignment of a sample and the standard substance and a peak pattern of a solubility curve of the sample.
Owner:SHANGHAI VETERINARY RES INST CHINESE ACAD OF AGRI SCI
Gene chip for predicting RNA virus infected severe case as well as using method and application
InactiveCN111455105AEasy to useMicrobiological testing/measurementMicroorganism based processesCXCR4Viral infection
The invention discloses a gene chip for predicting RNA virus infected severe case. The gene chip comprises probes for capturing the following genes of ACE, ANGPT2, ASRD, CD55, FAAH, GLDC, IFITM3, IL1A, IL1B, IL1RN, IL6, IL10, IL17, IL28B, IRAK3, LGALS1, LRRC16A, MBL-2, NAMPT, NFE2L2, PI3, POPDC3, PPFIA1, SP-A2, SP-B, ST3GAL1, TLR1, TLR3, TMPRSS2, TNFA, VEGF, XKR3, ACYP2, BCL2L1, CTC1, CXCR4, NFY1,OBFC1, PXR, RTEL1, TERC, TERT, ZNF208, ZNF311, and ZNF676.
Owner:山东端泉健康科技有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com